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Malaria remains one of the major health hazards, 
with high associated morbidity and mortality in 
addition to having a crippling effect on the economy. 
Worldwide, malaria is the cause of morbidity in 300-
500 million people annually, out of whom, 2-3 
1
million die . The disease is endemic within most 
tropical and subtropical regions of the world but 90% 
of all malaria deaths currently occur in Sub-Saharan 
Africa. In Africa, official figures show that a child 
dies of malaria every 45 seconds and the disease is 
2   responsible for 20% of all childhood deaths . In
Zambia, an estimated 3 million cases are said to 
occur every year and in the year 2006, the estimated 
3 number of deaths because of the disease was 6,484 
.The parasites responsible for malaria include P. 
falciparum, P. vivax, P. ovale and P. malariae. P. 
vivax and P. ovale exhibit the exoerythrocytic stage 
responsible for relapses, but of critical importance in 
Sub-Saharan region is P. falciparum.
P. falciparum has become resistant to chloroquine 
rendering chloroquine unreliable for both 
chemoprophylaxis and treatment of Malaria in P. 
falciparum endemic Sub-Saharan region including 
Zambia. To overcome this problem, it is important to 
in te r rup t  the  t r ansmiss ion  o f  mala r ia .  
Chemoprophylaxis, in endemic areas, is 
recommended for pregnant women and for those at 
high risk of severe malarial disease (e.g. severe 
anemia). It is also important for healthy travelers 
prior to visit to endemic areas. Antimalarial 
chemoprophylaxis currently relies on mefloquine, 
doxycycline and chloroquine for blood stage 
(suppressive) prophylaxis and primaquine and 
atovaquone-proguanil (Malarone) for liver stage 
4                (causal) prophylaxis .
   
A chemoprophylactic drug should, ideally, be taken 
infrequently to improve compliance and it should be 
very well tolerated and highly efficacious against all 
species of malaria. Primaquine eliminates the need 
for continued intake after the termination of 
exposure, in contrast to drugs active only against 
blood stages. For P.vivax, there has been very little 
focus with regards to identification of new family of 
compounds active against the hypnozoites. 
Primaquine, an 8-aminquinoline, has been the main 
stay therapy for past 60 years for clearing parasites 
from the liver. However, primaquine has a low 
therapeutic index, is associated with serious side-
effects, has a short half-life and daily dosing is 
5 needed . Tafenoquine, also known as WR238605, is 
a new 8- aminoquinoline which was synthesized to 
overcome deficiencies of primaquine. It has the 
potential to replace it as a prophylactic agent, since it 
has a much longer half-life, better therapeutic index 
and greater activity against both the blood and liver 
4 
stages of malaria .
CHEMISTRY  
Tafenoquine (  ) -8- (4–amino-1-methylbutyl) amino 
- 2,6 - dimethoxhy-4 methyl - 5 - (3-
trifluoromethylphenoxy) quinoline succinate}is a 
primaquine analogue. 
± 
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PHARMACODYNAMIC PROPERTIES AND 
ANTI-MALARIAL ACTIVITY
       
Degradation of hemoglobin by malarial parasite 
generates heme which is toxic to the parasite. Heme 
is then detoxified by the parasite itself through its 
conversion into insoluble pigment, hemozoin. 
Tafenoquine accumulates within the food vacuoles 
and inhibits the detoxification of heme to hemozoin 
by the malarial parasite. It does so by inhibiting 
hematin polymerization by binding to its -oxo 
dimer, thus inhibiting the formation of hemozoin, 
which consists of cyclic heme dimers arranged in an 
ordered crystalline structure through intermolecular 
hydrogen bonding. Tafenoquine, via its 
hydroxylated metabolites, stimulates the hexose 
monophosphate shunt, increases methemoglobin 
production and decreases glutathione levels in the 
cells. The pro-oxidant properties of its metabolites 
correlate with its exoerythrocytic schizontocidal 
action and also contribute to its erythrocytic 
6 
schizontocidal action .
Tafenoquine, in vitro, also demonstrates 
gametocidal and sporontocidal activity suggesting a 
7   
potential role in blocking of transmission . In 
preclinical studies, tafenoquine demonstrated 3-67 
times higher blood and tissue schizontocidal activity 
than primaquine. In vitro studies also demonstrated 
an apparent synergism of blood schizontocidal 
8 
activity with chloroquine and artemisinin . 
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Fig.1: Inhibitory Effects of Tafenoquine (B) on 
Heme  Detoxification (A) by Malarial Parasite.                                          
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Fig. 2: Structure of Tafenoquine
PHARMACOKINETIC PROPERTIES
In a phase I study in which a single dose was given to 
fasting subjects, linear kinetics was demonstrated at 
a dose of 400-600 mg base. On administration of 600 
mg to healthy volunteers as a single dose,  peak 
blood concentration of 417-489 ng/ml were 
 9 
observed
In a study done on Thai soldiers, minimum steady 
state concentration of 80-100 ng/ml were achieved 
with a loading dose of 1200 mg (400 mg/day for 3 
days) followed by monthly dose of 400 mg for 5 
months. The mean value of apparent volume of 
distribution seen was 1820 L. A standard high-fat 
meal has been found to increase its bioavailability 
9 by 40% .
Unlike primaquine, tafenoquine was also found to 
accumulate in red blood cells, with a whole blood to 
plasma concentration ratio of close to 1.8.  Such 
accumulation may contribute to the greater potency 
10of tafenoquine compared with primaquine .
TOLERABILITY
In clinical trials, oral tafenoquine was well tolerated, 
with only mild and transient gastrointestinal 
4
disturbances reported as possible side effects . 
In a double blind chemoprophylaxis trial in adult 
residents of Ghana, physical complaints involving 
the musculoskeletal, gastrointestinal and respiratory 
systems collectively accounted for 52%-70% of the 
total adverse events prompting health clinic visits. 
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The common events recorded included: 
Gastrointestinal ADRs like abdominal pain, 
gastritis, diarrhea; Musculoskeletal ADRs like 
backache, myalgia, polyarthralgia/arthralgia; as 
well as respiratory tract complaints including sore 
11, 12
throat . 
No trial, has reported dose-related adverse events so 
far. In the trial conducted in Kenya for prophylaxis 
against P. falciparum, dermatological events of mild 
to moderate severity were reported. Two hemolytic 
events also occurred during this study in volunteers 
who were later found to be glucose-6-phosphate 
12
dehydrogenase (G6PD) deficient .
Abnormal elevation of alanine amino transferase 
(ALT) level to more than 60 U/l has been reported in 
11
one of the trials .  Slight reduction in levels of 
haemoglobin was reported in trials conducted in 
 
endemic areas of Gabon and Ghana. These findings 
11
were, however, not found to be dose related .
CAUTION
It should not be prescribed to G6PD deficient 
patients and in pregnancy. 
THERAPEUTIC TRIALS
The first clinical study to report its prophylactic 
efficacy against P. falciparum malaria was done 
using a human challenge model in which volunteers 
were exposed to mosquitoes infected with a 
chloroquine sensitive clone (NF 54) of P. 
 
falciparum. A single 600 mg oral dose successfully 
prevented P. falciparum malaria in three of four non-
10immune volunteers in this challenge model . In 
clinical studies in western Kenya, where P. 
falciparum is holoendemic, tafenoquine given 
weekly at a dose of 200 and 400 mg provided 
protective efficacies of 86% and 89% respectively. 
An important observation in this trial was that, a 3-
day treatment regimen of tafenoquine 400 mg/day, 
followed by a weekly placebo, protected 82% 
participants for 7 weeks after commencement of 
9  
drug administration .
The prophylactic value of tafenoquine was further 
demonstrated in clinical studies in Ghana and 
Gabon, with protective efficacies of more than 86% 
using lower dose regimens of tafenoquine, such as 
11200 mg weekly . A randomized, placebo controlled 
study showed that after a loading dose of 
tafenoquine 400 mg/day for 3 days followed by 6 
months of single monthly doses of tafenoquine 400 
mg, the drug was 96% and 100% effective in 
preventing P. vivax and multi drug resistant P. 
13  falciparum malaria, respectively . In operational 
deployments in Thailand, tafenoquine as a single 
600 mg dose prevented P. vivax relapse in a follow 
14up of 8 weeks (protective efficacy of 92.6%) .
, Presently a safety study is being carried out to allow 
5a phaseII/III efficacy study to start in 2010 .
DOSE
As a prophylactic agent tafenoquine has been found 
to be significantly effective at doses ranging from 
600 mg as a single dose to 1200 mg as loading dose 
(400 mg/day for 3 days) followed by monthly doses 
4  of 400 mg . The recommended dosage for 
chemoprophylaxis of malaria, awaits conclusions 
from other Phase III trials.
Advantages and Disadvantages
The distinct advantages of Tafenoquine are:
1. Activity against blood and liver stage parasites
2. Additional gametocidal and sporontocidal 
activity.
3. Long half life
4. Potential drug of choice for  travelers to 
endemic areas for short periods 
5. Better compliance
6. Can be stopped immediately upon leaving 
endemic area
7. Chemoprophylactic properties against both P. 
falciparum and P. vivax
8. Has potential for radical cure of P. vivax 
Disadvantages associated with it are:
1. Safety in pregnancy has not yet been determined
2. There is a risk of hemolysis in G6PD deficiency
CONCLUSION
Tafenoquine is a long-acting analogue of 
primaquine. For non- immune travelers traveling to 
endemic areas for few weeks, tafenoquine, has the 
potential to be the drug of choice. Besides, on 
leaving the endemic region, tafenoquine need not be 
continued as it has an extended half-life and 
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potential transmission blocking properties and 
hence there are minimum chances of treatment 
failure due to non-compliance. Tafenoquine, 
besides chemoprophylaxis, also has the potential for 
radical cure of vivax malaria. Tafenoquine may also 
have a role in post exposure or terminal prophylaxis 
in travelers, in order to eliminate the hypnozoite 
stages of vivax malaria upon leaving an endemic 
area. However, prior to its administration, G6PD 
deficiency and/or pregnancy need to be ruled out.
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